Effects of anti-cardiolipin antibodies and IVIg on annexin A5 binding to endothelial cells: implications for cardiovascular disease

Scandinavian Journal of Rheumatology
A G FrostegårdJ Frostegård

Abstract

Anti-phospholipid antibodies (aPL), including anti-cardiolipin antibodies (aCL), are risk factors for cardiovascular disease (CVD) in the general population and in patients with the anti-phospholipid syndrome (APS; Hughes syndrome). APS may be primary but is also common in patients with systemic lupus erythematosus (SLE). The anti-coagulant protein annexin A5 (ANXA5) is implicated in CVD by interfering with phospholipids and aPL. ANXA5 binding to human umbilical venous endothelial cells (HUVECs) was determined by flow cytometry. When cells were cultured in serum from APS patients with a high aPL titre (aPL-S), binding of ANXA5 to HUVECs was reduced. Monoclonal immunoglobulin (Ig)G aPL against cardiolipin (mAb-CL) dose-dependently reduced ANXA5 binding to endothelium. Preincubation of intravenous (IV)Ig at therapeutically relevant doses with aPL-S and mAb-aCL restored ANXA5 binding to comparable levels when normal healthy serum (NHS) was used. By contrast, IVIg per se had the capacity to reduce ANXA5 binding to endothelium when added to NHS (but not to aPL-S). Decreased ANXA5 binding to endothelium, mediated by aPL, is a novel mechanism of atherothrombosis that can be countered by IVIg in vitro. IVIg per se could, to a lesser de...Continue Reading

References

Jul 17, 1997·The New England Journal of Medicine·J H RandP C Harpel
Nov 19, 1997·Arthritis and Rheumatism·L R SammaritanoJ E Salmon
Sep 3, 1998·The Journal of Clinical Investigation·A NicolettiG K Hansson
Jun 8, 2001·Current Atherosclerosis Reports·Y Sherer, Y Shoenfeld
Sep 8, 2001·The New England Journal of Medicine·M D Kazatchkine, S V Kaveri
Oct 17, 2001·Circulation·E SvenungssonJ Frostegård
Jan 24, 2002·The Journal of Experimental Medicine·V Michael HolersJane E Salmon
Feb 18, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Piero O BonettiAmir Lerman
Oct 14, 2004·European Neurology·S VucicD Cros
Nov 13, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Anna CederholmJohan Frostegård
Dec 4, 2004·The Journal of Biological Chemistry·Susana RavassaChris Reutelingsperger
Apr 22, 2005·The New England Journal of Medicine·Göran K Hansson
Jun 23, 2005·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Daphna ParanRonen Ben-Ami
Jun 25, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Johan Frostegård
Nov 17, 2005·The Annals of Pharmacotherapy·Sunita Bond StentonKerry Wilbur
Nov 23, 2005·Circulation·Yehuda ShoenfeldYaniv Sherer
Dec 6, 2005·Immunobiology·Anna Cederholm, Johan Frostegård
Jun 30, 2006·Thrombosis and Haemostasis·Patricia CasaisMaria A Lazzari
Jul 28, 2007·Scandinavian Journal of Rheumatology·K K SallaiP Gergely
Sep 1, 2007·Scandinavian Journal of Rheumatology·D ParanY Schwarz

❮ Previous
Next ❯

Citations

Dec 29, 2010·Clinical Reviews in Allergy & Immunology·P Roux-LombardN Vuilleumier
Mar 19, 2013·Rheumatology·Rabih NayfeMunther A Khamashta
Jul 5, 2011·Arthritis Research & Therapy·Johan Frostegård
Jul 16, 2014·Journal of the American Academy of Dermatology·Babak MonshiKlemens Rappersberger
Feb 9, 2013·Prostaglandins & Other Lipid Mediators·Helena DomeijJohan Frostegård
May 7, 2011·Autoimmunity Reviews·Cristiano AlessandriGuido Valesini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.